Evaluation of double filtration plasmapheresis, thermofiltration, and low-density lipoprotein adsorptive methods by crossover test in the treatment of familial hypercholesterolemia patients.
A comparative assessment has been made regarding efficacy and safety of the double filtration plasmapheresis (DFPP), thermofiltration (TFPP), and low-density lipoprotein (LDL) adsorptive (PA) methods by making a crossover test on heterozygous familial hypercholesterolemia patients. Treatments by DFPP, TFPP (secondary membrane Evalux 5A), and PA (Liposorber LA-40) were carried out 5 times each, with a 2-week interval, in 5 patients with heterozygous familial hypercholesterolemia. The same plasma separator (Plasmacure PS-60, polysulfone) was used in all cases, and the volume of plasma processed was set at 4 L. High removal rates were obtained of total cholesterol, LDL cholesterol, triglycerides TG, and apolipoprotein B (apoB) by all three methods, and no differences were observed. Lipoprotein (a), apoA-2, apoC-3, fibrinogen, and immunoglobulin M (IgM) showed significantly high removal rates by the DFPP and TFPP methods compared with the PA method. The sieving coefficient of albumin and high-density lipoprotein (HDL) cholesterol at 2 and 4 L of plasma processed exhibited high permeabilities using all three methods. Supplementing albumin was not necessary. An increase of the transmembrane pressure was observed in 1 case treated by DFPP but was not observed when using the TFPP or PA method. No changes were observed in serum interleukin 1beta (IL-1beta) or tumor necrosis factor-alpha (TNF-alpha) before and after treatment by any of the three methods. No remarkable side effects were observed using either the DFPP or TFPP method. The DFPP and TFPP methods showed efficacy and safety that was not inferior to the PA method in conventional LDL apheresis, and the dead-end method of the filter operation without the discarding of plasma was shown to be possible.
Suzuki
M
M
Tokyo-Tokatsu Clinic Hospital, Chiba, Japan.
Yamane
S
S
Matsugane
T
T
Nobuto
T
T
Azuma
N
N
Nishide
T
T
Shinomiya
M
M
Saito
K
K
Sasaki
N
N
Nosé
Y
Y
D000327:Adsorption; D000328:Adult; D016633:Apolipoprotein A-II / Q000097:blood / Q000302:isolation & purification; D001055:Apolipoproteins B / Q000097:blood / Q000302:isolation & purification; D001056:Apolipoproteins C / Q000097:blood / Q000302:isolation & purification; D001774:Blood Chemical Analysis; D001798:Blood Proteins / Q000378:metabolism; D018592:Cross-Over Studies; D005260:Female; D005340:Fibrinogen / Q000302:isolation & purification; D005374:Filtration; D006358:Hot Temperature; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000628:therapy*; D007075:Immunoglobulin M / Q000302:isolation & purification; D007375:Interleukin-1 / Q000378:metabolism; D017270:Lipoprotein(a) / Q000302:isolation & purification; D008077:Lipoproteins, LDL / Q000097:blood / Q000302:isolation & purification; D008079:Lipoproteins, VLDL / Q000097:blood / Q000302:isolation & purification; D008297:Male; D008875:Middle Aged; D010956:Plasmapheresis / Q000592:standards*; D014280:Triglycerides / Q000097:blood / Q000302:isolation & purification; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D016633:Apolipoprotein A-II; D001055:Apolipoproteins B; D001056:Apolipoproteins C; D001798:Blood Proteins; D007075:Immunoglobulin M; D007375:Interleukin-1; D017270:Lipoprotein(a); D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D005340:Fibrinogen